All News about Acorda Therapeutics, Inc. - Common Stock
![](https://mms.businesswire.com/media/20230511005653/en/1596352/5/Acorda_Logo-Color_Print.jpg)
From Acorda Therapeutics
Via Business Wire
![](https://investorplace.com/wp-content/uploads/2021/03/penny-stocks-1.jpg)
![](https://mms.businesswire.com/media/20230510005117/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](/next-assets/images/schema-image-default.png)
Via Benzinga
![](https://investorplace.com/wp-content/uploads/2021/04/wall-street.jpg)
![](/next-assets/images/schema-image-default.png)
Via Benzinga
![](https://mms.businesswire.com/media/20230508005309/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230504005726/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230424005261/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230403005358/en/1596352/5/Acorda_Logo-Color_Print.jpg)
From Acorda Therapeutics
Via Business Wire
![](https://mms.businesswire.com/media/20230327005219/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230309005345/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230307005326/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230306005798/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230214005861/en/1596352/5/Acorda_Logo-Color_Print.jpg)
Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement
February 14, 2023
From Acorda Therapeutics
Via Business Wire
![](https://mms.businesswire.com/media/20230131006066/en/1596352/5/Acorda_Logo-Color_Print.jpg)
Acorda Therapeutics to Present at Sequire Biotechnology Conference
January 31, 2023
From Acorda Therapeutics
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
January 23, 2023
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
January 05, 2023
Via Benzinga
![](https://mms.businesswire.com/media/20230105006013/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20221222005261/en/1596352/5/Acorda_Logo-Color_Print.jpg)
Acorda Therapeutics Announces Revised Long-Term Financial Guidance
December 22, 2022
From Acorda Therapeutics
Via Business Wire
![](https://mms.businesswire.com/media/20221220005771/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20221205005244/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20221111005323/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_21094.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/11/08/image16.jpg?width=1200&height=800&fit=crop)
![](https://mms.businesswire.com/media/20221104005393/en/1596352/5/Acorda_Logo-Color_Print.jpg)
From Acorda Therapeutics
Via Business Wire
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_20521.jpeg?width=1200&height=800&fit=crop)
![](https://mms.businesswire.com/media/20221101006228/en/1596352/5/Acorda_Logo-Color_Print.jpg)
Acorda Therapeutics Reports Third Quarter 2022 Financial Results
November 01, 2022
From Acorda Therapeutics
Via Business Wire
![](https://cdn.benzinga.com/files/images/story/2022/11/02/image29.jpeg?width=1200&height=800&fit=crop)
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free